Selma Machat is a state-certified nurse, coordinator of the ALS center, in the Neurology department of the Limoges University Hospital. After obtaining her nursing diploma in 1990 in Tulle, she worked in all France until 1998 and then joined the CHU de Limoges. In 2000, she started working in the hospitalization sector of the neurology department before becoming the coordinating nurse of the ALS center in 2003.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.